Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Reporting Date: August 8, 2006
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The period reflects the adoption of new accounting standards for stock-based compensation (SFAS 123R) and ongoing strategic cost reduction initiatives.
Key Financial Metrics
| Metric (Millions, except per share) | Q2 2006 | Q2 2005 | YTD 2006 | YTD 2005 |
|---|---|---|---|---|
| Net Sales | $4,161.4 | $3,987.1 | $8,229.3 | $7,892.9 |
| Gross Profit | $1,287.6 | $1,322.6 | $2,440.7 | $2,629.2 |
| Operating Profit | $544.1 | $636.2 | $964.5 | $1,273.8 |
| Net Income | $377.6 | $421.8 | $652.7 | $871.9 |
| Diluted EPS | $0.82 | $0.88 | $1.41 | $1.81 |
| Cash from Operations (YTD) | $1,118.7 (YTD 2006) | $1,082.7 (YTD 2005) | ||
| Cash from Operations (Q2) | ||||
| Total Debt (Current + Long-Term) | $3,669.7 (as of June 30, 2006) | |||
| Cash and Equivalents | $337.4 (as of June 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.4% in Q2 and 4.3% YTD, driven by a 2% increase in net selling prices and 1% volume growth. Personal Care and Health Care segments showed strong volume growth, while Consumer Tissue volumes declined in North America and Europe following price increases.
- Profitability Decline: Operating profit decreased 14.5% in Q2 and 24.3% YTD. This decline was primarily due to $89.4 million in strategic cost reduction charges in Q2 (totaling $298.0 million YTD) and significant cost inflation (approx. $100 million in Q2) related to raw materials, energy, and distribution.
- Accounting Change: Adoption of SFAS 123R (Share-Based Payment) effective Jan 1, 2006, resulted in a $10.9 million charge in Q2 and reduced net income by $7.3 million compared to prior accounting methods.
- Segment Performance:
- Personal Care: Operating profit up 4.3% (Q2) due to volume growth offsetting inflation.
- Consumer Tissue: Operating profit down 12.7% (Q2) due to volume declines and cost inflation.
- Health Care: Operating profit up 19.5% (Q2) driven by volume and price increases.
Guidance, Outlook, and Risks
- Strategic Cost Reductions: The company expects cumulative pretax charges of $1.0 to $1.1 billion through 2008, targeting annual pretax savings of at least $350 million by 2009. Full-year 2006 charges are expected to total approximately $500 million.
- Capital Allocation:
- Capital Spending: Targeted between $900 million and $1 billion for the full year 2006.
- Share Repurchases: Targeted at $750 million for the full year 2006. Approximately $284 million was spent YTD.
- Dividends: Cash dividends declared were $0.49 per share for Q2.
- Outlook: Management anticipates further improvement in the second half of the year despite inflationary pressures, driven by innovation, growth in developing markets, and cost reductions.
- Risks:
- Inflation: Continued pressure from raw material costs (polymers, fiber) and energy prices.
- Synthetic Fuel: Potential phase-out of tax credits if domestic oil prices exceed statutory limits.
- Foreign Exchange: Fluctuations in currency rates, particularly the Euro, impact translation adjustments.
Investor Verification Checklist
- Cost Inflation Impact: Verify the sustainability of margin recovery given the $100 million+ inflationary headwinds cited in Q2.
- Strategic Charge Execution: Monitor the timeline and actual savings realization of the $1.0-$1.1 billion cost reduction program against the 2008 completion target.
- Consumer Tissue Volumes: Assess whether volume declines in North America and Europe following price hikes are temporary or indicative of long-term demand elasticity.
- Synthetic Fuel Tax Credits: Review updates on the phase-out of tax credits based on average annual domestic oil prices.
- Share Count Reduction: Confirm the pace of share repurchases against the $750 million annual target to gauge EPS accretion.